| Catalog No. | HY550016 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Human |
|---|
| Isotype | IgG1-nd |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | Vimentin, VIM |
|---|
| Concentration | 4.12mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | P08670 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -449°C. |
|---|
| Alternate Names | CLNG11,CAS:499212-74-7 |
|---|
| Background | Pritumumab is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab recognizes vimentin expressing on the cell surface of the malignant tumor. Pritumumab can be used for glioblastoma research. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
